Literature DB >> 28289991

Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.

Dongting Liu1, Xiaohai Ma2, Jiayi Liu1, Lei Zhao1, Hui Chen1, Lei Xu1, Zhonghua Sun3, Zhanming Fan4.   

Abstract

The purpose of this study was to compare different semi-automated late gadolinium enhancement (LGE) quantification techniques using gadobutrol and gadopentetate dimeglumine contrast agents with regard to the diagnosis of fibrotic myocardium in patients with hypertrophic cardiomyopathy (HCM). Thirty patients with HCM underwent two cardiac MRI protocols with use of gadobutrol and gadopentetate dimeglumine. Contrast-to-noise ratio (CNR) between LGE area and remote myocardium (CNRremote), between LGE area and left ventricular blood pool (CNRpool), and signal-to-noise ratio (SNR) in LGE were compared. The presence and quantity of LGE were determined by visual assessment. With signal threshold versus reference mean (STRM) based thresholds of 2 SD, 5 SD, and 6 SD above the mean signal intensity (SI) of reference myocardium, the full-width at half-maximum (FWHM) technique was used. The volume and segments of the LGE area were compared between the two types of contrast agents. LGE was present in 26 of 30 (86.6%) patients in both protocols. The CNRremote of fibrotic myocardium in gadobutrol and gadopentetate dimeglumine agents was 26.82 ± 14.24 and 21.46 ± 10.59, respectively (P < 0.05). The CNRpool was significantly higher in gadobutrol (9.32 ± 7.64 vs. 6.39 ± 6.11, P < 0.05). The SNR was higher in gadobutrol (33.36 ± 14.35 vs. 27.53 ± 10.91, P < 0.05). The volume of scar size in MR images acquired with gadobutrol were significantly higher than those with gadopentetate dimeglumine (P < 0.05), and the STRM of 5 SD technique showed the greatest agreement with visual assessment (ICC = 0.99) in both examinations. There was no significant difference in fibrotic segments of the fibrotic myocardium in the LGE area (P < 0.05). This study proved that the Gadobutrol was an effective contrast agent for LGE imaging with superior delineation of fibrotic myocardium as compared to gadopentetate dimeglumine. The 5 SD technique yields the closest approximation of the extent of LGE identified by visual assessment.

Entities:  

Keywords:  Cardiovascular magnetic resonance (CMR); Contrast agent; Gadobutrol; Gadopentetate dimeglumine; Hypertrophic cardiomyopathy (HCM); Late gadolinium enhancement (LGE)

Mesh:

Substances:

Year:  2017        PMID: 28289991     DOI: 10.1007/s10554-017-1101-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  40 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Waren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Int J Cardiovasc Imaging       Date:  2002-02       Impact factor: 2.357

2.  Single-centre survey of the application of cardiovascular magnetic resonance in clinical routine.

Authors:  Florian von Knobelsdorff-Brenkenhoff; Angelika Bublak; Sana El-Mahmoud; Ralf Wassmuth; Christian Opitz; Jeanette Schulz-Menger
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-06-26       Impact factor: 6.875

3.  Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging.

Authors:  Caitlin J Harrigan; Dana C Peters; C Michael Gibson; Barry J Maron; Warren J Manning; Martin S Maron; Evan Appelbaum
Journal:  Radiology       Date:  2010-11-02       Impact factor: 11.105

4.  Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.

Authors:  Tahir Durmus; Rene Schilling; Patrick Doeblin; Alexander Huppertz; Bernd Hamm; Matthias Taupitz; Moritz Wagner
Journal:  Invest Radiol       Date:  2012-03       Impact factor: 6.016

5.  Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.

Authors:  Matthias Voth; Martin Rosenberg; Josy Breuer
Journal:  Invest Radiol       Date:  2011-11       Impact factor: 6.016

Review 6.  Value of 1.0- M gadolinium chelates: review of preclinical and clinical data on gadobutrol.

Authors:  Bernd Tombach; Walter Heindel
Journal:  Eur Radiol       Date:  2002-02-21       Impact factor: 5.315

7.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

8.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

9.  Quantification of late gadolinium enhanced CMR in viability assessment in chronic ischemic heart disease: a comparison to functional outcome.

Authors:  Aernout M Beek; Olga Bondarenko; Farshid Afsharzada; Albert C van Rossum
Journal:  J Cardiovasc Magn Reson       Date:  2009-03-09       Impact factor: 5.364

10.  Single-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T.

Authors:  Moritz Wildgruber; Thomas Stadlbauer; Michael Rasper; Alexander Hapfelmeier; Otto Zelger; Hans-Henning Eckstein; Martin Halle; Ernst J Rummeny; Armin M Huber
Journal:  Invest Radiol       Date:  2014-11       Impact factor: 6.016

View more
  6 in total

1.  Heterogeneity of longitudinal and circumferential contraction in relation to late gadolinium enhancement in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction.

Authors:  Keita Sakamoto; Noriko Oyama-Manabe; Osamu Manabe; Tadao Aikawa; Yasuka Kikuchi; Harue Sasai-Masuko; Masanao Naya; Kohsuke Kudo; Fumi Kato; Nagara Tamaki; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2017-11-09       Impact factor: 2.374

2.  Cardiovascular imaging 2017 in the International Journal of Cardiovascular Imaging.

Authors:  Johan H C Reiber; Amer Alaiti; Hiram G Bezerra; Johan De Sutter; Paul Schoenhagen; Arthur E Stillman; Nico R L Van de Veire
Journal:  Int J Cardiovasc Imaging       Date:  2018-06       Impact factor: 2.357

3.  Feature-tracking cardiac magnetic resonance method: a valuable marker of replacement fibrosis in hypertrophic cardiomyopathy.

Authors:  Nahid Rezaeian; Leila Hosseini; Negar Omidi; Mahya Khaki; Homa Najafi; Kianoosh Kasani; Mostafa Mousavizadeh; Yasaman Khalili; Mohammad Mehdi Hemmati Komasi; Yaser Toloueitabar; Sanaz Asadian
Journal:  Pol J Radiol       Date:  2022-05-16

4.  Electrocardiography based prediction of hypertrophy pattern and fibrosis amount in hypertrophic cardiomyopathy: comparative study with cardiac magnetic resonance imaging.

Authors:  Chul Hwan Park; Hyemoon Chung; Yoonjung Kim; Jong-Youn Kim; Pil-Ki Min; Kyung-A Lee; Young Won Yoon; Tae Hoon Kim; Byoung Kwon Lee; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon; Eui-Young Choi
Journal:  Int J Cardiovasc Imaging       Date:  2018-05-04       Impact factor: 2.357

5.  Tissue characterisation and myocardial mechanics using cardiac MRI in children with hypertrophic cardiomyopathy.

Authors:  Sudeep Sunthankar; David A Parra; Kristen George-Durrett; Kimberly Crum; Joshua D Chew; Jason Christensen; Frank J Raucci; Meng Xu; James C Slaughter; Jonathan H Soslow
Journal:  Cardiol Young       Date:  2019-11-26       Impact factor: 1.093

Review 6.  Gadobutrol: A Review in Contrast-Enhanced MRI and MRA.

Authors:  Lesley J Scott
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.